Bio View (XTAE:BIOV) Moat Score: 0/10 (As of Aug. 31, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:BIOV Bio View Ltd XTAE:BIOV
41 GF Score
Price ₪0.82
GF Value ₪1.71
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Bio View Moat Score?

Bio View has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Bio View has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bio View might have No Moat - No discernible moat.

Bio View  (XTAE:BIOV) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bio View Moat Score Related Terms

XTAE:BIOV
41GF Score
Bio View Ltd XTAE:BIOV
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bio View (XTAE:BIOV) Overvalued in 2026?

Based on GuruFocus' analysis, Bio View stock appears to be undervalued. The current stock price of ₪0.82 is trading 52.3% below its estimated GF Value™ of ₪1.71. GuruFocus considers Bio View to be Possible Value Trap.

Key valuation signals for XTAE:BIOV:

  • Moat Score: 0
  • GF Value™: ₪1.71 vs. price of ₪0.82 (52.3% below fair value)
  • GF Score™: 41/100 with 5 warning signs

No single metric tells the full story. See the XTAE:BIOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio View Business Description

Address 3 Pekeris Street, Rehovot, ISR, 7670203
Bio View Ltd is an Israel based company engaged in the research, development, manufacture, marketing, and sale of computerized systems for identification of rate cells and test for detection of cancer. It manufactures and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, pathology clinical and research laboratories. Geographically, the group has its business presence in Israel, USA, and other countries, of which majority of the revenue is derived from the USA.
41GF Score

Get the complete analysis for XTAE:BIOV

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.82
Price
₪1.71
GF Value